SANA Sana Biotechnology, Inc.
Legal ·
The Washington federal suit names Sana (Nasdaq: SANA), CEO Steven D. Harr and former CFO Nathan Hardy over SC291 statements. A second amended complaint was filed May 26, 2026, and the case is stayed.
Sana sold 20,895,522 shares at $3.35 plus pre-funded warrants for 1,492,537 more, with about $70.0 million in estimated net proceeds. It reported about $90.1 million in cash at July 31, 2025 and estimates $40.0 million to $45.0 million in facility impairments.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $132.0 million | $215.7 million |
| Net income (loss) | -$244.2 million | -$266.8 million |
| Cash from operations | -$143.8 million | -$223.2 million |
| Cash and equivalents | $71.9 million | $127.6 million |
| Short-term investments | $66.5 million | $24.9 million |
Our latest story on this, dated Aug 10, 2026: "Sana Biotechnology securities class action is stayed after second amended complaint". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 6, 2025: "Sana Biotechnology prices $75.0 million offering at $3.35 a share". The story links the filing or release it is based on. Read the story.
Sana Biotechnology, Inc. trades under the ticker SANA on NASDAQ.
Sana Biotechnology, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Sana Biotechnology, Inc. is 1770121. Its filings are on SEC EDGAR.
299,360,637 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Sana Biotechnology, Inc. under United States.
Our directory classifies Sana Biotechnology, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Sana Biotechnology, Inc. is US7995661045.
aibio.space lists Sana Biotechnology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Sana Biotechnology, Inc. reported a net loss of $244.2 million for the fiscal year ended Dec 31, 2025, and used $143.8 million of cash in operations, per its annual report to the SEC.
$132.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$160.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Sana Biotechnology, dated Aug 10, 2026: "Sana Biotechnology securities class action is stayed after second amended complaint". The Washington federal suit names Sana (Nasdaq: SANA), CEO Steven D. Harr and former CFO Nathan Hardy over SC291 statements. A second amended complaint was filed May 26, 2026, and the case is stayed. Source.
Reported a financing. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio